Novo Nordisk begins study of Lexicon oral obesity drug

The study is investigating the safety and tolerability of LX9851, how it moves through the body and its physiological and ...
FiercePharma

Persistent Lexicon still working to get an audience with FDA on Type 1 diabetes prospect

Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...
FiercePharma

5 years after initial FDA rejection, Lexicon prepares to resubmit Type 1 diabetes hopeful Zynquista

Ever since its first FDA rejection five years ago, Lexicon Pharmaceuticals hasn’t given up hope on its Type 1 diabetes prospect sotagliflozin. Now, the company’s approval dreams could be coming into ...
Seeking Alpha

Lexicon targets late 2025 Phase 3 start for pilavapadin and expands LX9851 partnership with Novo Nordisk

Mike Exton, Chief Executive Officer, highlighted a pivotal exclusive license agreement with Novo Nordisk for LX9851, stating "this agreement grants Novo an exclusive worldwide license to develop, ...